StockData

Outlook Therapeutics vs Scholar Rock

OTLK and SRRK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How OTLK and SRRK compare

Scholar Rock is the larger company, worth 63 times as much as Outlook Therapeutics ($5.5B against $87.8M).

Outlook Therapeutics scores higher on the StockData Score (4 against 2 for Scholar Rock), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricOTLKSRRK
Size and price
Market cap$87.8M$5.5B
Share price$0.361$45.08
Change, 1 year−77.0%20.5%
Change, 5 years−98.7%67.1%
Beta (5Y)3.720.83
Employees17289
StockData Score
Total score4 (better)2
Valuation score00
Growth score00
Performance score00
Health score4 (better)2
Dividend score00
Valuation
P/B–21.6×
FCF yield–−5.4%
Profitability
Return on equity–−168%
Financial health
Debt / equity–0.77
Interest coverage–−38.0×
Current ratio0.817.02 (better)
Altman Z-score−40.776.59 (better)
Piotroski F-score11
Dividends and buybacks
Buyback yield−62.3%−4.6% (better)
Shareholder yield−62.3%−4.6% (better)
Ownership
Held by institutions8.4%114%
Held by insiders28.5%28.9%
Insider net buying, 12 months$7.9M (better)−$7.4M
Short interest, % of float20.4%27.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.